Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab + AMG 404 in R/R B-ALL
NCT04524455Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label, single-arm trial of zeluvalimab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced Dose-Limiting Toxicities up to 56 days and Number of Participants Who Experienced Treatment-Emergent Adverse Events up to 274 days. Started Oct 2020; status: completed.
02
Drugs
zeluvalimab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04524455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524455.